Evidence map›Paper›PMID 26868369›Full record

Trial reportHematology (Amsterdam, Netherlands)2016

Simulation of various randomization strategies for a clinical trial in sickle cell disease.

William J Meurer, Jason T Connor, Jeffrey Glassberg

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Hematology (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

William J Meurera Departments of Emergency Medicine and Neurology , University of Michigan , Ann Arbor , MI , USA.
Jason T Connorb Berry Consultants , Austin , TX , USA.
Jeffrey Glassbergd Departments of Emergency Medicine, Hematology and Medical Oncology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Funding

New York City Sickle Cell Implementation Science ConsortiumU01HL133997 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHARDSON, LYNNE D. · 2016 to 2021
$5.4M
MOUNT SINAI EMERGENCY MEDICINE RESEARCH CAREER DEVELOPMENT PROGRAMK12HL109005 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHARDSON, LYNNE D. · 2011 to 2015
$3.9M
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)K23HL119351 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GLASSBERG, JEFFREY AVINS · 2013 to 2017
$857k
Comparing Acute Pain Management Protocols for Patients with Sickle Cell DiseaseR34HL121224 · NHLBI · DUKE UNIVERSITY · PI TANABE, PAULA · 2014 to 2015
$745k
NHLBI NIH HHS K12 HL109005NHLBI NIH HHS K23 HL119351NHLBI NIH HHS R34 HL121224NHLBI NIH HHS U01 HL133997
6 · The paper itself

Abstract

objectiveTo use numerical simulation to evaluate various randomization strategies for a clinical trial in sickle cell disease (SCD).

methodsThe Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events trial* is a randomized, controlled, feasibility study of inhaled mometasone for individuals with SCD who do not have asthma. The target sample size is 45 patients and one goal is to limit imbalance with respect to two important covariates (1) hydroxyurea use and (2) historical emergency department (ED) utilization. We compared three methods of patient allocation (simple randomization, block randomization, and biased-coin adaptive randomization) using numerical simulation (10 000 trials). The primary outcome measure was the proportion of simulated trials with numerically apparent differences in the two covariates: hydroxyurea use (binary) and ED utilization (three-level ordinal).

resultsOverall, only 1.6% of simulated trials had any covariate comparison with P < 0.3 across groups for simple randomization, and 0% for both the block and adaptive randomization. In trials where the total sample size was 45 patients, the block randomization strategy achieved the greatest balance because participants were deterministically assigned to the treatment arm that balanced covariates. The adaptive strategy achieved similar results without deterministic treatment assignments even when trials included only 45 patients. DISCUSSION: Adaptive clinical trial designs have potential to mitigate some of the challenges that have hampered SCD trials. In small exploratory trials, even non-statistically significant differences in important covariates can threaten interpretability and external validity.

conclusionAdaptive randomization performed similarly to block randomization and offers advantages including better allocation concealment and less ability for investigators to predict the next assignment.

Indexed as

Models, BiologicalAnemia, Sickle CellFemaleHumansMaleMometasone FuroateRandom AllocationMometasone FuroateAdaptive clinical trialsBayesian statisticsClinical trialsSickle cell disease

Identifiers

PMID26868369
PMCPMC5012429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.